Urinary Tract Infection Testing Market By Infection Type, By Test Type, By End User, By Test Kit : Global Opportunity Analysis and Industry Forecast, 2021-2031

List of Tables

The global urinary tract infection testing market is anticipated to reach $1,027.4 million by 2031, increasing from $574 million in 2021 at a CAGR of 6.2% from 2022 to 2031.

The rise in the prevalence of chronic diseases such as kidney disease and diabetes, an increase in the preference of clinicians for complete urine analysis, the surge in demand for early disease detection, a rise in cases of hospital-acquired urinary tract infection, and an increase in the use of urine analysis tests are the key factors driving the growth of the urinalysis test market. In addition, the rise in demand for minimally invasive urine diagnostic procedures, the increase in adoption of advanced urine analysis testing procedures, and the surge in R&D activities for the introduction of novel and accurate diagnostic tests are some factors that support the growth of the UTI testing market.

The global market for urinary tract infection testing is anticipated to experience development challenges due to side effects associated with the usage of UTI medications. Frequent errors in the diagnosis and management of urinary tract infection testing can impede market expansion during the forecast period. The lack of identifiable symptoms associated with UTI, the absence of standard diagnostic criteria, and the high contamination of samples are some of the key hurdles to market expansion.

Urinary tract infection (UTI) is a common occurrence in females, during pregnancy, and in peri- and postmenopausal women. UTIs are associated with severe morbidity and death, and they impact the quality of life of the affected people. Antibiotic therapy is a successful treatment that shortens the duration of symptoms. The development of resistance, the undesirable effects of antibiotics, and other linked issues lead to the establishment of a research framework to discover alternate means to managing UTIs.

Natural techniques are widely employed in the treatment of numerous ailments to alleviate symptoms and improve overall health.The use of medicinal herbs in the treatment and prevention of numerous diseases has expanded recently]. Complimentary therapy with medicinal herbs is a study topic that may merit special consideration. It has been demonstrated that herbal remedies can be useful in the management of a certain form of UTI.

Treatment with non-antibiotic drugs is a good strategy to lower the chance of developing UTI and to decrease its symptoms. Natural elements, minerals, and probiotics are among several agents that draw interest. Co-formulation of medications in a single dose form can create a natural formulation that is useful for both preventive and therapeutic methods in the management of UTI because each of these medications operates through a separate mechanism.

The COVID-19 pandemic brought several uncertainties, leading to severe economic losses as various businesses across the world were at a standstill. The arrival of the COVID-19 pandemic negatively impacted the manufacturing and supply chain & logistics industries, adversely affecting the healthcare business. Governments and healthcare providers are facing unheard-of issues owing to COVID-19, which has also had an impact on the regulatory environment and procedures. Patients with COVID-19 who were hospitalized were reportedly diagnosed with urinary tract infections. But multiple examinations have revealed that people with COVID-19 did not have severe urinary tract symptoms. Antibiotics are used extensively in COVID-19 patients due to high levels of blood inflammatory indicators of bacterial infection such as elevated C-reactive protein and procalcitonin. The majority of these individuals, however, had microbiologically verified bacterial co-infection symptoms.

The key players profiled in the report include F. Hoffmann-La Roche Ltd, Stryker, Abbott, Siemens, Sysmex Corporation, Cardinal Health, Danaher, Quidel, Bio-Rad Laboratories, Inc., and ACON Labs.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the urinary tract infection testing market analysis from 2021 to 2031 to identify the prevailing urinary tract infection testing market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the urinary tract infection testing market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global urinary tract infection testing market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Test Kit

Home Test Kits
Laboratory Test Kits

By Infection Type

Urethritis
Cystitis
Pyelonephritis

By Test Type

Urinalysis
Urine Cultures
Susceptibility Testing

By End User

Hospitals
Diagnostic Laboratories
Research Institutes

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- United Arab Emirates
- South Africa
- Rest of LAMEA

Key Market Players

Thermo Fisher Scientific, Inc.
Bio-Rad Laboratories
Danaher Corporation
ACON Laboratories Inc.
Cardinal Health Inc.
Stryker Corporation
SYSMEX CORPORATION
Abbott Laboratories
Roche AG
LabCorp(Laboratory Corporation of America Holdings).

Product Code: A31362

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
3.6. Key Regulation Analysis
3.7. Market Share Analysis
3.8. Patent Landscape
3.9. Regulatory Guidelines
3.10. Value Chain Analysis

CHAPTER 4: URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Urethritis
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Cystitis
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Pyelonephritis
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Urinalysis
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Urine Cultures
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Susceptibility Testing
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: URINARY TRACT INFECTION TESTING MARKET, BY END USER

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospitals
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Diagnostic Laboratories
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Research Institutes
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT

7.1. Overview
- 7.1.1. Market size and forecast
7.2. Home Test Kits
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by region
- 7.2.3. Market share analysis by country
7.3. Laboratory Test Kits
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by region
- 7.3.3. Market share analysis by country

CHAPTER 8: URINARY TRACT INFECTION TESTING MARKET, BY REGION

8.1. Overview
- 8.1.1. Market size and forecast By Region
8.2. North America
- 8.2.1. Key trends and opportunities
- 8.2.2. Market size and forecast, by Infection Type
- 8.2.3. Market size and forecast, by Test Type
- 8.2.4. Market size and forecast, by End User
- 8.2.5. Market size and forecast, by Test Kit
- 8.2.6. Market size and forecast, by country
  - 8.2.6.1. U.S.
  - 8.2.6.1.1. Key market trends, growth factors and opportunities
  - 8.2.6.1.2. Market size and forecast, by Infection Type
  - 8.2.6.1.3. Market size and forecast, by Test Type
  - 8.2.6.1.4. Market size and forecast, by End User
  - 8.2.6.1.5. Market size and forecast, by Test Kit
  - 8.2.6.2. Canada
  - 8.2.6.2.1. Key market trends, growth factors and opportunities
  - 8.2.6.2.2. Market size and forecast, by Infection Type
  - 8.2.6.2.3. Market size and forecast, by Test Type
  - 8.2.6.2.4. Market size and forecast, by End User
  - 8.2.6.2.5. Market size and forecast, by Test Kit
  - 8.2.6.3. Mexico
  - 8.2.6.3.1. Key market trends, growth factors and opportunities
  - 8.2.6.3.2. Market size and forecast, by Infection Type
  - 8.2.6.3.3. Market size and forecast, by Test Type
  - 8.2.6.3.4. Market size and forecast, by End User
  - 8.2.6.3.5. Market size and forecast, by Test Kit
8.3. Europe
- 8.3.1. Key trends and opportunities
- 8.3.2. Market size and forecast, by Infection Type
- 8.3.3. Market size and forecast, by Test Type
- 8.3.4. Market size and forecast, by End User
- 8.3.5. Market size and forecast, by Test Kit
- 8.3.6. Market size and forecast, by country
  - 8.3.6.1. Germany
  - 8.3.6.1.1. Key market trends, growth factors and opportunities
  - 8.3.6.1.2. Market size and forecast, by Infection Type
  - 8.3.6.1.3. Market size and forecast, by Test Type
  - 8.3.6.1.4. Market size and forecast, by End User
  - 8.3.6.1.5. Market size and forecast, by Test Kit
  - 8.3.6.2. UK
  - 8.3.6.2.1. Key market trends, growth factors and opportunities
  - 8.3.6.2.2. Market size and forecast, by Infection Type
  - 8.3.6.2.3. Market size and forecast, by Test Type
  - 8.3.6.2.4. Market size and forecast, by End User
  - 8.3.6.2.5. Market size and forecast, by Test Kit
  - 8.3.6.3. France
  - 8.3.6.3.1. Key market trends, growth factors and opportunities
  - 8.3.6.3.2. Market size and forecast, by Infection Type
  - 8.3.6.3.3. Market size and forecast, by Test Type
  - 8.3.6.3.4. Market size and forecast, by End User
  - 8.3.6.3.5. Market size and forecast, by Test Kit
  - 8.3.6.4. Spain
  - 8.3.6.4.1. Key market trends, growth factors and opportunities
  - 8.3.6.4.2. Market size and forecast, by Infection Type
  - 8.3.6.4.3. Market size and forecast, by Test Type
  - 8.3.6.4.4. Market size and forecast, by End User
  - 8.3.6.4.5. Market size and forecast, by Test Kit
  - 8.3.6.5. Italy
  - 8.3.6.5.1. Key market trends, growth factors and opportunities
  - 8.3.6.5.2. Market size and forecast, by Infection Type
  - 8.3.6.5.3. Market size and forecast, by Test Type
  - 8.3.6.5.4. Market size and forecast, by End User
  - 8.3.6.5.5. Market size and forecast, by Test Kit
  - 8.3.6.6. Rest of Europe
  - 8.3.6.6.1. Key market trends, growth factors and opportunities
  - 8.3.6.6.2. Market size and forecast, by Infection Type
  - 8.3.6.6.3. Market size and forecast, by Test Type
  - 8.3.6.6.4. Market size and forecast, by End User
  - 8.3.6.6.5. Market size and forecast, by Test Kit
8.4. Asia-Pacific
- 8.4.1. Key trends and opportunities
- 8.4.2. Market size and forecast, by Infection Type
- 8.4.3. Market size and forecast, by Test Type
- 8.4.4. Market size and forecast, by End User
- 8.4.5. Market size and forecast, by Test Kit
- 8.4.6. Market size and forecast, by country
  - 8.4.6.1. China
  - 8.4.6.1.1. Key market trends, growth factors and opportunities
  - 8.4.6.1.2. Market size and forecast, by Infection Type
  - 8.4.6.1.3. Market size and forecast, by Test Type
  - 8.4.6.1.4. Market size and forecast, by End User
  - 8.4.6.1.5. Market size and forecast, by Test Kit
  - 8.4.6.2. Japan
  - 8.4.6.2.1. Key market trends, growth factors and opportunities
  - 8.4.6.2.2. Market size and forecast, by Infection Type
  - 8.4.6.2.3. Market size and forecast, by Test Type
  - 8.4.6.2.4. Market size and forecast, by End User
  - 8.4.6.2.5. Market size and forecast, by Test Kit
  - 8.4.6.3. India
  - 8.4.6.3.1. Key market trends, growth factors and opportunities
  - 8.4.6.3.2. Market size and forecast, by Infection Type
  - 8.4.6.3.3. Market size and forecast, by Test Type
  - 8.4.6.3.4. Market size and forecast, by End User
  - 8.4.6.3.5. Market size and forecast, by Test Kit
  - 8.4.6.4. South Korea
  - 8.4.6.4.1. Key market trends, growth factors and opportunities
  - 8.4.6.4.2. Market size and forecast, by Infection Type
  - 8.4.6.4.3. Market size and forecast, by Test Type
  - 8.4.6.4.4. Market size and forecast, by End User
  - 8.4.6.4.5. Market size and forecast, by Test Kit
  - 8.4.6.5. Australia
  - 8.4.6.5.1. Key market trends, growth factors and opportunities
  - 8.4.6.5.2. Market size and forecast, by Infection Type
  - 8.4.6.5.3. Market size and forecast, by Test Type
  - 8.4.6.5.4. Market size and forecast, by End User
  - 8.4.6.5.5. Market size and forecast, by Test Kit
  - 8.4.6.6. Rest of Asia-Pacific
  - 8.4.6.6.1. Key market trends, growth factors and opportunities
  - 8.4.6.6.2. Market size and forecast, by Infection Type
  - 8.4.6.6.3. Market size and forecast, by Test Type
  - 8.4.6.6.4. Market size and forecast, by End User
  - 8.4.6.6.5. Market size and forecast, by Test Kit
8.5. LAMEA
- 8.5.1. Key trends and opportunities
- 8.5.2. Market size and forecast, by Infection Type
- 8.5.3. Market size and forecast, by Test Type
- 8.5.4. Market size and forecast, by End User
- 8.5.5. Market size and forecast, by Test Kit
- 8.5.6. Market size and forecast, by country
  - 8.5.6.1. Brazil
  - 8.5.6.1.1. Key market trends, growth factors and opportunities
  - 8.5.6.1.2. Market size and forecast, by Infection Type
  - 8.5.6.1.3. Market size and forecast, by Test Type
  - 8.5.6.1.4. Market size and forecast, by End User
  - 8.5.6.1.5. Market size and forecast, by Test Kit
  - 8.5.6.2. Saudi Arabia
  - 8.5.6.2.1. Key market trends, growth factors and opportunities
  - 8.5.6.2.2. Market size and forecast, by Infection Type
  - 8.5.6.2.3. Market size and forecast, by Test Type
  - 8.5.6.2.4. Market size and forecast, by End User
  - 8.5.6.2.5. Market size and forecast, by Test Kit
  - 8.5.6.3. United Arab Emirates
  - 8.5.6.3.1. Key market trends, growth factors and opportunities
  - 8.5.6.3.2. Market size and forecast, by Infection Type
  - 8.5.6.3.3. Market size and forecast, by Test Type
  - 8.5.6.3.4. Market size and forecast, by End User
  - 8.5.6.3.5. Market size and forecast, by Test Kit
  - 8.5.6.4. South Africa
  - 8.5.6.4.1. Key market trends, growth factors and opportunities
  - 8.5.6.4.2. Market size and forecast, by Infection Type
  - 8.5.6.4.3. Market size and forecast, by Test Type
  - 8.5.6.4.4. Market size and forecast, by End User
  - 8.5.6.4.5. Market size and forecast, by Test Kit
  - 8.5.6.5. Rest of LAMEA
  - 8.5.6.5.1. Key market trends, growth factors and opportunities
  - 8.5.6.5.2. Market size and forecast, by Infection Type
  - 8.5.6.5.3. Market size and forecast, by Test Type
  - 8.5.6.5.4. Market size and forecast, by End User
  - 8.5.6.5.5. Market size and forecast, by Test Kit

CHAPTER 9: COMPETITIVE LANDSCAPE

9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2021

CHAPTER 10: COMPANY PROFILES

10.1. Abbott Laboratories
- 10.1.1. Company overview
- 10.1.2. Key Executives
- 10.1.3. Company snapshot
10.2. Roche AG
- 10.2.1. Company overview
- 10.2.2. Key Executives
- 10.2.3. Company snapshot
10.3. Thermo Fisher Scientific, Inc.
- 10.3.1. Company overview
- 10.3.2. Key Executives
- 10.3.3. Company snapshot
10.4. Bio-Rad Laboratories
- 10.4.1. Company overview
- 10.4.2. Key Executives
- 10.4.3. Company snapshot
10.5. Danaher Corporation
- 10.5.1. Company overview
- 10.5.2. Key Executives
- 10.5.3. Company snapshot
10.6. ACON Laboratories Inc.
- 10.6.1. Company overview
- 10.6.2. Key Executives
- 10.6.3. Company snapshot
10.7. Cardinal Health Inc.
- 10.7.1. Company overview
- 10.7.2. Key Executives
- 10.7.3. Company snapshot
10.8. Stryker Corporation
- 10.8.1. Company overview
- 10.8.2. Key Executives
- 10.8.3. Company snapshot
10.9. SYSMEX CORPORATION
- 10.9.1. Company overview
- 10.9.2. Key Executives
- 10.9.3. Company snapshot
10.10. LabCorp(Laboratory Corporation of America Holdings).
- 10.10.1. Company overview
- 10.10.2. Key Executives
- 10.10.3. Company snapshot